



16 February 2012
EMA/92686/2012
Press Office

Overview of invented names reviewed in January 2012 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 13-16 February 2012

	NRG meeting 24 Jan 2012		NRG meeting 27 March 2012		NRG meeting 29 May 2012		NRG meeting 28 June 2012**		NRG meeting 03 Oct 2012		NRG meeting 20 Nov 2013		2012	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed invented names	74	48												
Justification for retention of invented name *	5	1												

*In case of objections to the proposed invented name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMEA website.

	NRG meeting 24 Jan 2012		NRG meeting 27 March 2012		NRG meeting 29 May 2012		NRG meeting 28 June 2012**		NRG meeting 03 Oct 2012		NRG meeting 20 Nov 2012		2012	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Objections														
Total number of objections raised	75	99												
Criterion - Safety concerns														
Similarity with other Invented name	55	79												
Conveys misleading therapeutic/pharmaceutical connotations	3													
Misleading with respect to composition	2	1												
Criterion - INN concerns														
Similarity with INN		1												
Inclusion of INN stem	2	2												



	NRG meeting 24 Jan 2012	NRG meeting 27 March 2012	NRG meeting 29 May 2012	NRG meeting 28 June 2012**	NRG meeting 03 Oct 2012	NRG meeting 20 Nov 2012	2012
Criterion - Other public health concerns							
Unacceptable qualifiers							
Conveys a promotional message	1	4					
Appears offensive or has a bad connotation							
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	2						
Similarity between name of prodrug and related active substance							

See *Guideline on the Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure (CPMP/328/98 Rev. 5)* for detailed explanations of criteria used.

**Meeting cancel due to the Olympics